Designs of the analyzed prospective studies | ||||
---|---|---|---|---|
Study | Phase | Treatment regimens | MGMT promoter status | Absolut patient numbers |
TEMSIROLIMUS (EORTC 26082–22081) | III | 1. Conventional RT with 60 Gy plus temsirolimus 25 mg once a week beginning 7 days before initiation of radiotherapy. Adjuvant cycles of temsirolimus 25 mg once a week until progression. | Unmethylated | 19 |
2. Conventional RT with 60 Gy plus 75 mg/m2/d TMZ during RT. Up to six cycles of adjuvant TMZ for 5 days every 28 days with 150 mg/m2/d for the first adjuvant cycle and 200 mg/m2/d for the following cycles. | ||||
ENZASTAURIN (H6Q-MC-S039) | II | 1. Conventional RT with 60 Gy plus Enzastaurin 250 mg b.i.d. until progression or a maximum of 3 years. | Unmethylated | 13 |
2. Conventional RT with 60 Gy plus 75 mg/m2/d TMZ during RT. Up to six cycles of adjuvant TMZ for 5 days every 28 days with 150 mg/m2/d for the first adjuvant cycle and 200 mg/m2 for the following cycles. | ||||
CENTRIC (EORTC 26071–22072) | III | 1. Conventional RT with 60 Gy plus 75 mg/m2/d TMZ during RT plus Cilengitide 2000 mg twice a week beginning 7 days before initiation of radiotherapy until day 77 or progression. Up to six cycles of adjuvant TMZ for 5 days every 28 days with 150 mg/m2/d for the first adjuvant cycle and 200 mg/m2/d for the following cycles. | Methylated | 18 |
2. Conventional RT with 60 Gy plus 75 mg/m2/d TMZ during RT. Up to six cycles of adjuvant TMZ for 5 days every 28 days with 150 mg/m2/d for the first adjuvant cycle and 200 mg/m2/d for the following cycles. |